Oberland pours up to $400M into MeiraGTx eye gene therapies
Oberland pours up to $400M into MeiraGTx eye gene therapies (BioPharma Dive.)
Oberland Capital
Private
Oberland Capital is a healthcare-focused investment firm providing structured capital to commercial-stage and late-stage clinical biopharma companies. In 2026 it announced up to $400M in financing to MeiraGTx to support eye gene therapy commercialization.
Company Info
Sector:Investment Firm / Healthcare
Headquarters:New York, New York, USA
Founded:2013
Website:oberlandcapital.com/